指南与共识血管炎

大动脉炎管理:为2018年EULAR大血管血管炎管理推荐更新提供依据的系统性文献综述

Management of Takayasu arteritis: a systematic literature review informing the 2018 update of the EULAR recommendation for the management of large vessel vasculitis.
指南 / 共识 · RMD Open · 2019-09-23

该系统性文献综述旨在为2018年EULAR大血管血管炎管理推荐更新收集证据,检索Medline、Embase和Cochrane数据库,共纳入287篇文章。结果发现男性并发症更多,主要并发症、高龄、进展性病程和较弱炎症反应与更差预后相关;糖皮质激素为公认一线治疗,传统免疫抑制剂和TNF抑制剂在病例系列中有效,托珠单抗在随机对照试验中未达到主要终点但结果仍优于安慰剂;证据主要来自低级别观察性研究。

要点

  • 男性大动脉炎患者并发症多于女性。
  • 主要并发症、高龄、进展性病程和较弱炎症反应提示预后更差。
  • 糖皮质激素为公认一线治疗,血管干预宜在疾病 inactive 时进行。

核心结论

  • 指导大动脉炎监测与治疗的证据主要来自低级别观察性研究,未来需更高质量研究。

研究设计与样本

  • 进行了两项独立的系统性文献综述,一项关于诊断与监测,另一项关于药物与手术治疗。
  • 采用预定义的PICO策略检索Medline、Embase和Cochrane数据库,共选取287篇文章。
  • 因异质性大未进行荟萃分析,结果汇总于总结表。

主要发现

  • 男性似乎比女性有更多并发症。
  • 主要并发症、高龄、进展性病程和较弱炎症反应与更不利预后相关。
  • 未找到关于最佳疾病监测方案的详细证据。
  • 未找到指导大动脉炎治疗的高质量证据。
  • 糖皮质激素被广泛接受为一线治疗,传统免疫抑制剂和肿瘤坏死因子抑制剂在病例系列和未对照研究中显示有益。

关键数值与推荐

  • 糖皮质激素被广泛接受为一线治疗。
  • 传统免疫抑制剂和肿瘤坏死因子抑制剂在病例系列和未对照研究中显示有益。
  • 托珠单抗在随机对照临床试验中未达到主要终点(至复发时间),但结果仍优于安慰剂。

临床怎么用

  • 糖皮质激素可作为大动脉炎的一线治疗。
  • 传统免疫抑制剂和肿瘤坏死因子抑制剂可用于治疗。
  • 血管操作宜在疾病不活动期进行以改善结局。

局限性

  • 证据主要来自观察性研究,证据级别低。
  • 相关异质性妨碍了荟萃分析。
  • 未找到关于最佳疾病监测方案的详细证据。
  • 未找到指导治疗的高质量证据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To collect available evidence on management of large vessel vasculitis to inform the 2018 update of the EULAR management recommendations. METHODS: Two independent systematic literature reviews were performed, one on diagnosis and monitoring and the other on drugs and surgical treatments. Using a predefined PICO (population, intervention, comparator and outcome) strategy, Medline, Embase and Cochrane databases were accessed. Eligible papers were reviewed and results condensed into a summary of findings table. This paper reports the main results for Takayasu arteritis (TAK). RESULTS: A total of 287 articles were selected. Relevant heterogeneity precluded meta-analysis. Males appear to have more complications than females. The presence of major complications, older age, a progressive disease course and a weaker inflammatory response are associated with a more unfavourable prognosis. Evidence for details on the best disease monitoring scheme was not found. High-quality evidence to guide the treatment of TAK was not found. Glucocorticoids are widely accepted as first-line treatment. Conventional immunosuppressive drugs and tumour necrosis factor inhibitors were beneficial in case series and uncontrolled studies. Tocilizumab failed the primary endpoint (time to relapse) in a randomised controlled clinical trial; however, results still favoured tocilizumab over placebo. Vascular procedures may be required, and outcome is better when performed during inactive disease. CONCLUSIONS: Evidence to guide monitoring and treatment of patients with TAK is predominantly derived from observational studies with low level of evidence. Therefore, higher-quality studies are needed in the future.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Águeda AF, Monti S, Luqmani RA, et al. Management of Takayasu arteritis: a systematic literature review informing the 2018 update of the EULAR recommendation for the management of large vessel vasculitis. RMD Open. 2019. PMID: 31673416. doi:10.1136/rmdopen-2019-001020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。